View Older Stories View More Recent Stories

Oct 26, 2022 05:49AM Exelixis (EXEL) Reports Promising Initial Dose-Escalation Results from Phase 1 JEWEL-101 Trial of XB002
Oct 26, 2022 04:00AM Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Oct 18, 2022 04:05PM Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
Oct 4, 2022 08:03AM Exelixis (EXEL) Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY)
Oct 4, 2022 08:00AM Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STE
Sep 10, 2022 03:00AM Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ES
Sep 8, 2022 06:22AM Exelixis (EXEL) Announces More Detailed Results of Phase 3 COSMIC-313 Trial in Advanced Kidney Cancer at ESMO
Sep 7, 2022 06:05PM Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
Sep 6, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
Aug 9, 2022 04:05PM Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 26, 2022 04:05PM Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Jul 11, 2022 08:01AM Exelixis (EXEL) Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved PFS in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney
Jul 11, 2022 08:00AM Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated
Jul 7, 2022 12:00AM Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Jul 5, 2022 04:05PM Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
Jun 21, 2022 08:00AM Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Jun 16, 2022 12:00AM Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
May 31, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
May 26, 2022 05:00PM Exelixis (EXEL) Reports Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab
May 26, 2022 05:00PM Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 26, 2022 05:00PM Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
May 10, 2022 04:05PM Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 4, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 3, 2022 08:00AM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Apr 26, 2022 04:05PM Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Apr 26, 2022 08:03AM Phathom Pharmaceuticals (PHAT) Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 14, 2022 08:00AM Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Apr 13, 2022 04:06PM Exelixis (EXEL) Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Apr 13, 2022 04:05PM Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Mar 25, 2022 08:49AM Exelixis (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Mar 25, 2022 08:49AM Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Mar 14, 2022 04:11PM Exelixis (EXEL) Announces Final OS Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Mar 14, 2022 04:05PM Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver
Mar 2, 2022 04:05PM Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March
Feb 17, 2022 04:05PM Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Feb 14, 2022 05:02PM Bristol-Myers Squibb (BMY) and Exelisis (EXEL) Report that Opdivo in Combination with CABOMETYX Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial
Feb 14, 2022 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal C
Feb 3, 2022 04:05PM Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
Jan 18, 2022 05:31PM Exelixis (EXEL) Reports Detailed Results for Cabozantinib in Combination with Immunotherapies
Jan 18, 2022 05:30PM Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
Jan 10, 2022 05:48AM Exelixis (EXEL) Reports Prelim Q4 Results; Issues 2022 Guidance and Key Milestones
Jan 9, 2022 04:00PM Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
Jan 6, 2022 08:00AM Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Jan 5, 2022 08:00AM Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
Jan 4, 2022 04:05PM Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
Jan 4, 2022 08:00AM Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Dec 17, 2021 08:05AM Exelixis (EXEL) Appoints Jacqueline Wright to Its Board
Dec 17, 2021 08:00AM Exelixis Elects Jacqueline Wright to Its Board of Directors
View More Recent Stories View Older Stories